World CB & CDx Boston 2026

Date: October 5, 2026 - October 8, 2026
Type: In-person
Location: North America
Areas of Interest: BioPharma, Liquid Biopsy, Oncology

We are thrilled to be back at the 16^th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.

Our team will be happy to see you join our Plenary Talk and our Co-hosted Engager with Myriad Genetics.

Plenary Talk on Tuesday, October 6^th, from 5.40 to 6.10 pm.

“The Power of Modular CGP: Enabling Precision Oncology Across Drug Development”

Mike Berger, PhD, Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

Julien Pontis, PhD, Head of CDx & Clinical Diagnostics, SOPHiA GENETICS

Join this session to explore how MSK-IMPACT® Flex powered with SOPHiA DDM™ is reshaping the future of precision medicine. In this session you will:

Explore the origins of MSK-IMPACT™ and its real-world impact on patient care.
Gain insights into the assay’s robust analytical performance at scale, enabling decentralized sites across the world to generate concordant and high-quality data.
Discover the agile and modular design of MSK-IMPACT® Flex powered with SOPHiA DDM™, which enhances testing efficiency through tailored biomarker coverage, while providing the flexibility to add biomarkers as needed.

Understand how a flexible, future-proof CGP infrastructure helps pharma keep pace with an evolving biomarker landscape, and how SOPHiA GENETICS is already delivering this across the drug development continuum through hands-on partnerships with key diagnostic players.

Add to calendar

Co-hosted Engager, coupled with a networking dinner, on Tuesday, October 6^th from 7.30 to 10.00 pm.

“Pioneering Precision Medicine: A New Model for CDx Development & Commercialization”

In this workshop, we will explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access in precision medicine.

This is an invitation-only engager session. If you are interested in attending, please contact the Hanson Wade team.

Add to calendar

Register Now

Facebook

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Organization(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services